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Abstract  
Background and purpose: We previously showed that Nociceptin/orphanin FQ opioid 
peptide (NOP) receptor agonists attenuate the expression of levodopa-induced dyskinesia 
in animal models of Parkinson’s disease. We now investigate the efficacy of two novel, 
potent and chemically distinct NOP receptor agonists, AT-390 and AT-403, to improve 
parkinsonian disabilities and attenuate dyskinesia development and expression. 
Experimental approach: Binding affinity and functional efficacy of AT-390 and AT-403 
at the opioid receptors were determined in radioligand displacement assays and in GTPγS 
binding assay respectively, conducted in Chinese hamster ovary cells. Their 
antiparkinsonian activity was evaluated in 6-hydroxydopamine hemilesioned rats whereas 
the antidyskinetic properties were assessed in 6-hydroxydopamine hemilesioned rats 
chronically treated with levodopa. The ability of AT-403 to inhibit the D1 receptor-
induced phosphorylation of striatal extracellular signal regulated kinase (ERK) was 
investigated. 
Key results: AT-390 and AT-403 selectively improved akinesia at low doses and 
disrupted global motor activity at higher ones. AT-403 palliated dyskinesia expression 
without causing sedation in a narrow therapeutic window, whereas AT-390 delayed AIMs 
appearance and increased their duration at doses causing sedation. AT-403 did not prevent 
the priming to levodopa, although it significantly inhibited dyskinesia on the first day of 
administration. AT-403 reduced the ERK phosphorylation induced by SKF38393 in vitro 
and by levodopa in vivo. 
Conclusions and Implications: NOP receptor stimulation can provide significant, albeit 
mild antidyskinetic effect, at doses not causing sedation. The therapeutic window, 
however, varies across compounds. AT-403 appears to be a potent and selective tool to 
investigate the role of NOP receptors in vivo.   
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Non standard abbreviations 
AIMs abnormal involuntary movements 
ALO axial, limb and orolingual 
CHO Chinese hamster ovary 
DA dopamine 
δ delta opioid peptide 
ERK extracellular signal regulated kinase 1 and 2 
κ kappa opioid peptide 
L-DOPA levodopa 
LID levodopa-induced dyskinesia 
µ mu opioid peptide 
MPTP 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
MSNs medium-sized spiny neurons 
N/OFQ nociceptin/orphanin FQ  
NOP nociceptin/orphanin FQ opioid peptide 
6-OHDA 6-hydroxydopamine
PD Parkinson’s disease 
SNr substantia nigra reticulata 
Page 3 of 45
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
4 
Introduction 
Nociceptin/Orphanin FQ (N/OFQ) and the N/OFQ opioid peptide receptor (NOP receptor) 
(previously known as Opioid Receptor Like 1 receptor) constitute a neuropeptide system 
carrying numerous structural and functional analogies with the classical opioid systems 
(Toll et al., 2016). Nonetheless, the pharmacology of the N/OFQ-NOP receptor is distinct 
from those of classical opioid receptor systems, since N/OFQ does not bind classical 
opioid receptors, and most classical opioid receptor ligands (e.g. naloxone) do not bind the 
NOP receptor (Calo et al., 2000; Zaveri, 2016). Because of its widespread distribution in 
the central nervous system, the N/OFQ-NOP receptor system is key in the regulation of 
multiple central functions, such as sensory nociceptive processing, mood, food intake, 
pain, reward and locomotion. Moreover, the N/OFQ-NOP receptor system is implicated in 
various neuropsychiatric disorders such as neuropathic pain (Lin et al., 2013), anxiety and 
depression (Gavioli et al., 2013), drug abuse (Cippitelli et al., 2016; Lutfy et al., 2016), 
and Parkinson’s disease (PD) (Marti et al., 2005; Viaro et al., 2008).  
As far as PD is concerned, preclinical models disclosed a potential role for NOP receptor 
agonists as antidyskinetic agents (Marti et al., 2012) . Acute central administration of 
N/OFQ or systemic administration of the small molecule NOP receptor agonist Ro 65-
6570 attenuated the severity of dyskinesia in 6-OHDA hemilesioned rats and 1-methyl-4-
phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated macaques chronically treated with 
levodopa (L-DOPA). Dyskinesia represents a major complication of L-DOPA 
pharmacotherapy of PD (Bastide et al., 2015); however, there are currently no drugs that 
can prevent dyskinesia development when chronically combined with L-DOPA in de novo 
PD patients (Bastide et al., 2015; Huot et al., 2013). Therefore, the identification of 
antidyskinetic drugs is an unmet clinical need. Since the antidyskinetic effect of NOP 
agonists was observed in rats after acute administration at doses that did not cause 
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hypolocomotion or sedation (Marti et al., 2012), effects typical of NOP receptor agonists 
(Zaveri, 2016), we hypothesized that NOP agonists may exert specific antidyskinetic 
effects and be clinically useful in PD patients that have already become dyskinetic due to 
chronic L-DOPA therapy. In our first proof-of-concept study, we used the NOP agonist Ro 
65-6570, which is only modestly selective for the NOP receptor, as the systemically-active 
agonist to replicate the effects of centrally administered N/OFQ. However, we did not 
specifically investigate whether N/OFQ or Ro 65-6570 worsened parkinsonian disabilities, 
which is worth investigating in view of the symptomatic effects of NOP receptor 
antagonists in 6-OHDA hemilesioned rats (Marti et al., 2005; Marti et al., 2004a; Marti et 
al., 2008; Volta et al., 2011), and other models of PD (Viaro et al., 2008; Visanji et al., 
2008; Volta et al., 2010).  
Further, we recently demonstrated that NOP receptor stimulation opposes D1 receptor 
signaling in striatum (Marti et al., 2012; Olianas et al., 2008). It is well known that 
upregulation of D1 signalling cascade in striatal medium-sized spiny GABAergic neurons 
(MSNs) projecting to SNr (the so-called direct pathway), underlies the appearance of 
dyskinesia (Bastide et al., 2015). In our previous study, we did not assess whether NOP 
receptor agonists, in addition to preventing expression of L-DOPA-induced dyskinesia 
(LID), a symptomatic effect, also attenuated the process of brain sensitization (priming) 
that underlies the development of dyskinesia when given chronically in combination with 
L-DOPA.  
We recently discovered two high affinity, highly selective NOP receptor agonists AT-390 
and AT-403, from two distinct chemical classes, which had greater than 100-fold 
selectivity over the μ, δ and κ opioid receptors We characterized these compounds for their 
functional activity and found them to be full agonists at the NOP receptor. AT-403 was 
recently characterized as a potent nonpeptide surrogate of the natural endogenous peptide 
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ligand N/OFQ, because it was found to have unbiased functional efficacy at the NOP G-
protein as well as the arrestin signalling pathway, like the natural ligand N/OFQ (Ferrari et 
al., 2017).  
With these highly selective NOP agonists in hand, we undertook the present study to more 
fully investigate the antiparkinsonian and antidyskinetic profiles of these two novel and 
selective NOP receptor agonists, AT-403 and AT-390. In the first series of experiments, 
AT-403 and AT-390 were acutely administered to 6-OHDA hemilesioned rats to assess 
whether they improve or worsen parkinsonian motor deficits. Next, AT-403 and AT-390 
were acutely administered to 6-OHDA hemilesioned, L-DOPA-primed dyskinetic rats to 
confirm that NOP receptor stimulation attenuates LID expression. Thirdly, to determine 
whether NOP receptor stimulation attenuates priming to L-DOPA, and therefore the 
development of dyskinesia, AT-403 was chronically administered to 6-OHDA 
hemilesioned rats in combination with L-DOPA for 20 days. Finally, to investigate 
whether AT-403 could specifically affect signalling pathways underlying dyskinesia, 
phosphorylation levels of striatal extracellular signal regulated kinase 1 and 2 (ERK), a 
D1-dependent biochemical correlate of LID (Santini et al., 2007; Valjent et al., 2005) were 
monitored both in vitro and ex-vivo.   
 
Methods 
Materials 
AT-403 (2-(1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-2-oxoindolin-3-yl)-N-
methylacetamide) (Ferrari et al., 2017) and AT-390 ((1-(1-(cis-4-
isopropylcyclohexyl)piperidin-4-yl)-1H-indole-2,3-diyl)dimethanol) were synthesized at 
Astraea Therapeutics (Mountain View, CA, USA) and were dissolved in 1% CH3COOH 
1M and 3% DMSO in water. Radioligands [
3
H]N/OFQ, [
3
H]DAMGO, and [
3
H]DPDPE 
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were obtained from the National Institute of Drug Abuse Drug Supply Program. 
[
3
H]U69593 and [
35
S]GTPS was purchased from Perkin Elmer. L-DOPA, benserazide, 6-
OHDA hydrobromide and d-amphetamine sulphate were purchased from Tocris 
Bioscience (Bristol, UK). L-DOPA, benserazide and d-amphetamine sulphate were 
dissolved in saline, 6-OHDA was dissolved in 0.02% ascorbic acid in saline 
Biochemical assays 
The binding affinities of AT-403 and AT-390 for the opioid receptors were determined in 
radioligand competition experiments using human opioid receptor-transfected Chinese 
hamster ovary (CHO) cells, as previously reported (Adapa et al., 1997; Zaveri et al., 2004). 
[
3
H]N/OFQ (130 Ci/mmol, 0.04 nM) was used as radioligand for the NOP receptor,
[
3
H]U69,593 (120 Ci/mmol, 0.2 nM)  for the κ receptor, [
3
H]DAMGO (120 Ci/mmol, 0.2
nM) for the µ receptor, and [
3
H]Cl-DPDPE (120 Ci/mmol, 0.2 nM) for the δ receptor. IC50
values were determined from at least six concentrations of test compound, and calculated 
using Graphpad/Prism (ISI, San Diego, CA). Ki values (nM) were derived from the Cheng-
Prusoff equation Ki=IC50/1+[L]/Kd) where [L] is the concentration of the radioligand.  
The functional efficacy of the compounds was determined by their ability to stimulate 
[
35
S]GTPγS binding to cell membranes, and compared to the standard agonists N/OFQ
(NOP), DAMGO (µ), U69,593 (κ) and DPDPE (δ), as previously described (Adapa et al., 
1997; Spagnolo et al., 2008; Zaveri et al., 2004). 
Animal Subjects 
Experiments were performed in accordance with the ARRIVE and BJP guidelines. 
Experimenters were blinded to treatments. Male Sprague-Dawley rats (150 g, 6 week old; 
Envigo, S. Pietro al Natisone, Italy) were housed in a standard facility with free access to 
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food (4RF21 standard diet; Mucedola, Settimo Milanese, Milan, Italy) and water, and kept 
under regular lighting conditions (12 hr dark/light cycle). Animals were housed in groups 
of 5 for a 55x33x20 cm polycarbonate cage (Tecniplast, Buguggiate, Varese, Italy) with a 
Scobis Uno bedding (Mucedola, Settimo Milanese, Milan, Italy) and environmental 
enrichments. The experimental protocols were approved by the Italian Ministry of Health 
(license n. 170/2013-B). Adequate measures were taken to minimize animal pain and 
discomfort. At the end of the experiments, rats were sacrificed with an overdose of 
isoflurane. Six male 2 month-old C57Bl6 mice were used for ERK studies in vitro. Mice 
were housed in a standard facility at Cardiff University, under regular conditions of light 
(12hr light/dark cycle), with food and water ad libitum.  
 
ERK measurement in vitro 
Adult mice were decapitated after cervical dislocation and brain slices were freshly 
prepared according to the protocol described in (Marti et al., 2012). The brains were 
rapidly removed and put on a cool glass plate filled with ice-cold sucrose-based 
dissecting solution (87 mM NaCl, 2.5 mM KCl, 7 mM MgCl2, 1 mM NaH2PO4, 75 mM 
sucrose, 25 mM NaHCO3, 10 mM D-glucose, 0.5 mM CaCl2, 2 mM kynurenic acid), 
carbogenated (95% O2, 5% CO2), and subsequently mounted on the vibratome stage 
(Vibratome, VT1000S-Leica Microsystems). Two-hundred (200) µm-thick slices were 
cut and transferred into a brain slice chamber (Brain slice chamber-BSC1 - Scientific 
System design Inc., Mississauga, ON, Canada) and allowed to recover for 1 hr at 32°C, 
with a constant perfusion of carbogenated artificial cerebrospinal fluid (ACSF: 124 mM 
NaCl, 5 mM KCl, 1.3 mM MgSO4, 1.2 mM NaH2PO4, 25 mM NaHCO3, 10 mM D-
glucose, 2.4 mM CaCl2). The D1 receptor agonist SKF38393 (100 µM) was applied for 
10 min in the presence of AT-403 (30 nM) or vehicle. After fixation in 4% PFA for 15 
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min at room temperature, slices were rinsed three times in PBS and cryoprotected in 
30% sucrose solution overnight at 4°C. On the following day, slices were further cut into 
18 µm-thick slices using a cryostat (Leica CM1850) and mounted onto SuperFrost Plus 
slides (Thermo Scientific). Immunohistochemistry was performed following the protocol 
described in (Papale et al., 2016): 1 hr after blocking in 5% normal goat serum and 0.1% 
Triton X-100 solution, slices were incubated overnight at 4°C with anti-phospho-p44/42 
MAP kinase (Thr202/Tyr204) (1:1000, Cell Signaling Technology cat. #4370L). 
Sections were then incubated with biotinylated goat anti-rabbit IgG (1:200, Vector 
Laboratories, cat. #BA-1000) for 2 hr at room temperature. Detection of the bound 
antibodies was carried out using a standard peroxidase-based method (ABC-kit, 
Vectastain, Vector Labs), followed by a DAB and H2O2 solution. Images were acquired 
from the striatum at 40X magnification using a brightfield microscope (Leica 
Macro/Micro Imaging System) and the number of pERK positive cells in the striatum 
was counted in each slice.  
 
Unilateral 6-OHDA lesion 
The unilaterally 6-OHDA lesioned rat, the most popular and best validated model of PD 
(Duty et al., 2011; Schwarting et al., 1996), was used to assess the ability of AT-403 and 
AT-390 to improve parkinsonian-like motor deficits. Unilateral lesion of dopaminergic 
neurons was induced under isoflurane anaesthesia as previously described (Marti et al., 
2005). Eight micrograms of 6-OHDA freebase (dissolved in 0.9% saline solution 
containing 0.02% ascorbic acid) were stereotaxically injected in the medial forebrain 
bundle according to following coordinates from bregma: antero-posterior= -4.4 mm, 
medio-lateral= -1.2, dorso-ventral=-7.8 mm below dura (Paxinos et al., 1986). Animals 
were pre-treated with antibiotics (Synulox™, 50 µL/Kg, i.p.). The wound was sutured and 
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infiltrated with 2% lidocaine solution (Esteve™). In order to select rats that were 
successfully hemilesioned, two weeks after 6-OHDA injection, rats were injected with a 
test dose of D-amphetamine (5 mg kg
-1
, i.p., dissolved in saline), and those performing >7
turns per minute in the direction ipsilateral to the lesion were enrolled in the study. In fact, 
this behaviour has been associated with >95% loss of striatal dopaminergic terminals 
(Marti et al., 2007) and extracellular dopaminergic levels (Marti et al., 2002).  
Behavioral Tests 
Bar Test. The bar test, also known as catalepsy test (Sanberg et al., 1988), measures the 
ability of the animal to react to an externally imposed position. The right and left forepaws 
were alternatively placed on three blocks of increasing heights (3, 6, 9 cm). The 
immobility time (in sec) of each forepaw on the blocks was recorded (the cut-off for each 
step was set at 20 sec).  
Drag Test. The drag test (Marti et al., 2005), modification of the “wheelbarrow test” 
(Schallert et al., 1979), measures the ability of the animal to balance its body posture using 
the forelimbs, in response to backward dragging. Each rat was gently lifted from the 
abdomen leaving the forepaws on the table and dragged backwards at a constant speed of 
20 cm sec
-1
 for a fixed distance of 1 m. Two different observers counted the number of
touches made by each forepaw. 
Rotarod Test. This test measures the ability of the animal to run on a rotating cylinder and 
provides different information on a variety of motor parameters such as coordination, 
balance, muscle tone, gait and motivation to run (Rozas et al., 1997). The fixed-speed 
rotarod test was employed using a previously validated protocol (Marti et al., 2005; Marti 
et al., 2004b). Animals were tested starting from 5 rpm, speed was stepwise increased by 5 
rpm every 180 sec, and total time spent on the rod was calculated. 
L-DOPA treatment and abnormal involuntary movements rating
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Rats that successfully performed the amphetamine test were treated for 20 days with L-
DOPA (6 mg kg
-1
 + benserazide 12 mg kg
-1
, s.c., once daily) to induce abnormal 
involuntary movements (AIMs), a correlate of LID, as previously described (Bido et al., 
2011; Marti et al., 2012; Mela et al., 2012; Mela et al., 2010; Paolone et al., 2015). This 
represents the best validated model of dyskinesia in rodents, (Bastide et al., 2015; Cenci et 
al., 1998; Cenci et al., 2007). Rats were observed for 1 min, every 20 min, during the 3 
hours that followed L-DOPA injection or until dyskinetic movements ceased. Dyskinetic 
movements were classified based in their topographical distribution into three subtypes 
(Cenci et al., 1998; Cenci et al., 2007): (1) Axial AIM, i.e., twisted posture or turning of 
the neck and upper body toward the side contralateral to the lesion; (2) forelimb AIM, i.e., 
jerky and dystonic movements and/or purposeless grabbing of the forelimb contralateral to 
the lesion; (3) orolingual AIM, i.e., orofacial muscle twitching, purposeless masticatory 
movement and contralateral tongue protrusion. Each AIM subtype was rated on a 
frequency scale from 0 to 4 (1, occasional; 2, frequent; 3, continuous but interrupted by an 
external distraction; 4, continuous and not interrupted by an external distraction). In 
addition, the amplitude of these AIMs was measured on a scale from 0 to 4 based on a 
previously validated scale (Cenci et al., 2007). Axial, Limb and Orolingual (ALO) AIMs 
total value were obtained as the sum of the product between amplitude and frequency of 
each observation (Cenci et al., 2007). Therefore the theoretical maximum ALO AIMs 
score is 432; to be considered fully dyskinetic an animal has to score ≥100. 
 
Western blot analysis 
Dyskinetic rats were treated with saline or AT-403 (0.1 mg kg
-1
), and 15 min later with L-
DOPA (6 mg kg
-1
 + benserazide 12 mg kg
-1
, s.c.). Thirty min after L-DOPA, rats were 
anesthetised with isoflurane, sacrificed by decapitation and striata rapidly dissected, frozen 
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on dry ice and stored at -80°C until analysis. Tissues were homogenized in lysis buffer 
(RIPA buffer, protease inhibitor cocktail and phosphatase inhibitor cocktail) and 
centrifuged at 13,000 rpm at 4°C for 15 min. Supernatants were collected and protein 
levels were quantified using the bicinchoninic acid protein assay kit (Thermo Scientific). 
Thirty micrograms of protein per sample were separated on a 4-12% gradient 
polyacrilamide precast gels (Bolt® 4-12% Bis-Tris Plus Gels, Life Technologies) in a 
Bolt® Mini Gel Tank apparatus (Life Technologies). Proteins were then transferred onto 
polyvinyldifluoride membrane, blocked for 60 min with 5% non-fat dry milk in 0.1% 
Tween20 Tris-buffered saline, and incubated overnight at 4°C with anti-Thr202/Tyr204-
phosphorylated ERK1/2 (pERK) rabbit monoclonal antibody (Merck Millipore, cat. #05-
797R, 1:1000) or with anti-ERK1/2 (totERK) rabbit polyclonal antibody (Merck Millipore 
cat. #06-182, 1:5000). Membranes were washed, then incubated 1 hr at room temperature 
with horseradish peroxidase-linked secondary antibodies (Merck Millipore, cat. #12-348, 
1:5000). Immunoreactivity was visualized by enhanced chemiluminescence (ECL) 
detection kit (Perkin Elmer), images were acquired using the ChemiDoc MP System 
quantified using the ImageLab Software (Bio-Rad). Membranes were then stripped and re-
probed with rabbit monoclonal anti-tubulin antibody (Merck Millipore, cat. #04-1117, 
1:50000). Data were analyzed by densitometry, and the optical density of specific pERK or 
totERK bands was normalized to the corresponding tubulin levels. 
 
Experimental protocols and design 
Experiments were performed according to BJP guidelines. Overall, 149 rats and 6 mice 
were used in this study. Timelines of the different studies are illustrated in Fig. 1. 
Motor behavior in 6-OHDA hemilesioned, L-DOPA naïve rats 
Page 12 of 45
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
13 
 
Fifty-two (52) rats were hemilesioned with 6-OHDA, 40 of which passed the amphetamine 
testing after 2 weeks, meeting the selection criteria (Fig. 1). Ten days later, these rats were 
subjected to the bar, drag and rotarod tests repeated in a fixed sequence as a training. When 
motor performance was reproducible (usually after 7-10 days), rats were randomized and 
treated with AT-403 (0.001, 0.01, 0.03, 0.1 and 0.3 mg kg
-1
), AT-390 (0.03, 0.1, 1 and 3 
mg kg
-1
), the NOP receptor antagonist SB-612111, AT-403 + SB-612111 or vehicle. Rats 
were tested 3-4 times, and a 3-day washout was allowed between treatments. Motor 
activity was assessed 30 and 90 min after AT-403 administration, or 60, 120 and 180 min 
after AT-390 administration, and expressed as absolute values. 
LID expression 
Seventy-three (73) rats were hemilesioned with 6-OHDA, 60 of which passed the selection 
criteria (Fig. 1). Fifty-two (52) 6-OHDA hemilesioned rats were chronically treated with 
L-DOPA, whereas 8 were left untreated as a control for the ERK analysis. At the end of L-
DOPA treatment, 24 fully dyskinetic rats (ALO AIMs score ≥100) were randomized to L-
DOPA (6 mg kg
-1
 plus benserazide 12 mg kg
-1
, s.c.) in combination with AT-403 (0.03 and 
0.1 mg kg
-1
), AT-390 (0.3, 1 and 3 mg kg
-1
) or vehicle. Each animal was tested 3-4 times, 
with a 3-day washout allowed between treatments. On separate days, motor performance 
was measured using the rotarod test, both before (OFF L-DOPA) and 60 min after L-
DOPA administration (ON L-DOPA), to evaluate whether the potential antidyskinetic 
effect was associated with an improvement of global motor activity. This time point was 
chosen based on the ALO AIMs time-course, which showed a peak 60-80 min after L-
DOPA administration (Bido et al., 2011; Marti et al., 2012; Mela et al., 2012; Mela et al., 
2010; Paolone et al., 2015). Sixteen (16) additional, fully dyskinetic rats were used for 
ERK analysis and parsed into two groups, one treated with saline plus L-DOPA and 
another with 0.1 mg kg
-1
AT-403 plus L-DOPA. 
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LID induction 
Twenty-four (24) naïve rats were hemilesioned with 6-OHDA, 18 of which passed the 
selection criteria and were treated with L-DOPA in combination with vehicle (6 mg kg
-1
plus benserazide 12 mg kg
-1
, s.c.; n=9) or AT-403 (0.03 mg kg
-1
, s.c., given 15 min before
L-DOPA; n=9) for 20 days. ALO AIMs score was performed at days 1, 5, 10, 15 and 20.
At the end of the 20-day treatment, all animals were allowed a 24-hr washout, and then 
given a L-DOPA challenge (dosage as above) in order to verify whether the antidyskinetic 
effect was due a reduction of priming rather than a symptomatic effect. During these 3 
weeks, motor activity was assessed in 4 different occasions (days 3, 8, 14, 19) with the 
rotarod test performed both OFF and ON L-DOPA (60 min after injection).  
Data presentation and statistical analysis 
The data and statistical analysis comply with the recommendations on experimental design 
and analysis in pharmacology (Curtis et al., 2015). Motor performance was expressed as 
absolute values (time on bar or rod, number of steps), and statistically analysed using 
PRISM 6.0 (GraphPad Software Inc., San Diego, CA) with two-way repeated measure 
(RM) ANOVA followed by the Bonferroni test (Fig. 2 and Fig. 4) or one-way ANOVA 
followed by the Newman-Keuls test (Fig. 3). ALO AIMs score was expressed as absolute 
values and statistically analysed with two-way RM ANOVA followed by Bonferroni test 
(time-course; Fig. 5A, 6A, 7A-E) or one-way ANOVA followed by the Newman-Keuls 
test (cumulative AIMs score; Fig. 5B and 6B). Rotarod performance in dyskinetic animals 
was expressed as time on rod (in sec) and analysed with two-way ANOVA followed by 
Bonferroni test (Fig. 5C and 6D). In vitro ERK data (Fig. 8A) were analysed using two-
way ANOVA followed by the Bonferroni test, whereas ex-vivo ERK data were analysed 
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by one-way ANOVA followed by the Newman-Keuls test. Statistical significance was set 
at p<0.05.  
 
Nomenclature of Targets and Ligands  
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015). 
 
Results 
Receptor and GTPγS binding 
AT-403 and AT-390 showed high nanomolar affinity for the NOP receptor expressed in 
CHO cells (Ki of 1.1 nM and 0.9 nM, respectively), and significantly lower affinity for the 
other opioid receptors (Table 1). The selectivity ratios for NOP over classical opioid 
receptors were: AT-390, 59-fold (µ), 125-fold (δ) and 95-fold (κ); AT-403, 89-fold (µ), 
3700-fold (δ) and 1420-fold (κ). Both compounds were characterized for their functional 
activity in the [
35
S]GTPγS binding assay using a range of concentrations up to 10 µM. In 
this assay, AT-403 and AT-390 mimicked the stimulatory effects of N/OFQ at the NOP 
receptor, showing similar efficacy (110% and 104%, respectively) and slightly lower 
potency (EC50: N/OFQ 3.6 nM, AT-403 6.3 nM AT-390 15.2 nM; Table 1), suggesting 
they are full agonists at the NOP receptor. Higher concentrations of AT-403 and AT-390 
appeared to stimulate the µ opioid receptor, although with significantly lower potency 
(overall <60%). Potency selectivity ratios of AT-403 and AT-390 for NOP over the µ 
receptor were 33-fold and 10-fold, respectively, and maximal stimulation was 33% and 
54% of positive controls, respectively (Table 1).  
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Effect on parkinsonian disabilities 
Previous studies showed that i.c.v. injection of N/OFQ has a biphasic effect on motor 
behaviour in naïve animals. To investigate whether a highly selective NOP receptor 
agonist could affect parkinsonian-like symptoms, AT-403 was administered systemically 
(s.c.) in the 0.001-0.3 mg kg
-1 
dose-range, and motor activity evaluated by the bar, drag and 
rotarod tests 30 and 90 min after injection. After preliminary screening, we observed that 
rats (n=3) administered with AT-403 0.3 mg kg
-1
 were unable to perform for 1 hour after 
drug administration, due to profound, though reversible, sedation/hypolocomotion. 
Therefore, the study was continued with the lower doses.  
In the bar test (Fig. 2A), ANOVA showed a significant effect of treatment (F4,2=5.99; 
p=0.0004), time (F2,130=57.33; p<0.0001) and time x treatment interaction (F8,130=6.07; 
p<0.0001) at the contralateral paw. Post hoc analysis revealed that AT-403 caused a 
transient reduction (30 min time point) of the time on bar at the contralateral paw at 0.01 
mg kg
-1
, showing more profound and long lasting effects at the higher doses (Fig. 2A). AT-
403 did not affect stepping activity at the contralateral paw (Fig. 2B). In the rotarod test 
(Fig. 2C), ANOVA did not showed an overall effect of treatment (F4,2=1.45; p=0.22), but a 
significant effect of time (F2,130=6.34; p=0.0023) and time × treatment interaction 
(F8,130=3.08; p=0.0008). Post hoc analysis revealed a significant decrease  of rotarod 
performance with the highest dose of AT-403 (0.1 mg kg
-1
) at 30 min after administration. 
To investigate the NOP selectivity of AT-403, the effects of systemic administration of 
AT-403 (0.01 mg kg
-1
, s.c.) in combination with the NOP receptor antagonist SB-612111 
were evaluated in the bar test (Fig. 3). SB-612111 was administered at a dose (0.01 mg kg
-
1
, s.c.) ineffective per se on motor behaviour (Marti et al., 2013). ANOVA showed a 
significant effect of treatment (F3,31=3.77; p=0.020) (Fig. 3). Post hoc analysis revealed 
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that AT-403 reduced the time on bar and SB-612111, ineffective by itself, prevented such 
effect.  
To confirm that NOP receptor stimulation dually modulated parkinsonian disabilities, 
behavioural observations were extended up to 180 min after AT-390 injection (Fig. 4). In a 
dose-finding experiment, a profound and long lasting sedation/hypolocomotion was 
observed with 3 mg kg
-1
 AT-390. Animals were unable to perform for at least 2 hours after 
drug administration; therefore, the study was continued with lower doses. Very much like 
AT-403, AT-390 improved the immobility time at the contralateral paw (Fig. 4A; 
treatment F3,3=5.39 p=0.0047; time F3,84=11.09, p<0.0001, time × treatment interaction 
F9,84=4.59 p<0.0001). A transient reduction of immobility time was observed at 120 min 
after injection of 0.1 mg kg
-1
 AT-390, whereas a sustained (up to 180 min) inhibition was 
observed with both 0.3 and 1 mg kg
-1
 AT-390, with the effect of the former showing a 
tendency to fade over time. In the drag test, no significant effect was observed at the 
contralateral paw (Fig. 4B). Finally, in the rotarod test (Fig. 4C), transient inhibition was 
detected at 60 min with all doses (treatment F3,3=4.07 p=0.016; time F3,84=19.65 p<0.0001; 
time × treatment interaction F9,84=5.54 p<0.0001). The effect was particularly dramatic 
with 1 mg kg
-1
 AT-390. A milder, though significant, inhibition was still observed at 2 
hours with 0.3 and 1 mg kg
-1
 AT-390, whereas the effect disappeared 3 hrs after treatment. 
Effects on AIMs expression  
To investigate whether NOP receptor stimulation prevents the expression of AIMs, AT-
403 and AT-390 were administered 15 min before an L-DOPA challenge in dyskinetic rats 
(Fig. 5). AT-403 caused a delay in LID appearance without significantly affecting the 
overall duration of the response to L-DOPA (treatment F2,8=7.92; p=0.0012; time 
F8,352=47.47, p<0.0001; time ×treatment interaction F16,352=15.17, p<0.0001; Fig. 5A). 
ANOVA on itemized cumulative AIMs (Fig. 5B) showed that AT-403 at 0.1 mg kg
-1
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markedly inhibited all AIM subtypes whereas AT-403 at 0.03 mg kg
-1
 cause a mild and 
selective inhibition of limb AIMs (Fig. 5B). The beneficial effect of 0.1 mg kg
-1
 AT-403 
was accompanied by overt sedation/hypolocomotion within the first hour after compound 
administration. This was also evident when rats were challenged on the rotarod. Indeed, 
control animals displayed dramatic reduction (75%) of the rotarod performance at peak 
dyskinesia (Fig 5C), whereas animals treated with 0.03 mg kg
-1
 AT-403 were significantly 
less impaired (55% reduction). Animals treated with 0.1 mg kg
-1
 AT-403 instead, were 
inhibited as much as controls, indicating that the absence of dyskinetic movements was not 
associated with better rotarod performance.  
AT-390 significantly modified AIMs time-course, although in a quite unexpected way 
(Fig. 6A). While 0.3 mg kg
-1
 AT-390 did not significantly affect the response to L-DOPA, 
1 mg kg
-1
 AT-390 caused a delay in AIMs appearance and a prolongation of AIMs 
duration up to 240 min after L-DOPA injection, such that the overall response to L-DOPA 
was quantitatively unchanged (treatment F2,13=0.14; p=0.87, time F13,260=51.43; p<0.0001, 
time × treatment: F26,260=9.34, p<0.0001 ) (Fig 6A). To confirm this profile, we injected a 
higher dose of AT-390 (3 mg kg
-1
) in a small number of rats (n=4, Fig 6C). The effect was 
particularly dramatic as a further rightward shift in the time-course was observed, with 
longer delay and duration of the AIMs response. As observed for AT-403, a clear 
sedative/hypolocomotive effect was associated with the delayed response to 1 mg kg
-1
 AT-
390. Indeed, even though AIMs were significantly reduced at 60 min after L-DOPA 
injection, rotarod performance was dramatically impaired (90%), similar to controls (Fig. 
6D).  
Effect on AIMs development (priming protocol) 
The experiments in dyskinetic animals revealed that only AT-403 (0.03 mg kg
-1
) provided 
an acute, albeit mild, antidyskinetic effect, without causing primary 
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sedation/hypolocomotion. We therefore tested whether this dose could attenuate AIMs 
development when chronically combined to L-DOPA. 
Animals treated with L-DOPA alone developed severe AIMs within the first week of 
treatment (Fig. 7A). Then, dyskinesia scores remained maximal until the end of the 20-day 
period. AT-403 did not confer overall protection against AIMs development, although AT-
403 treated rats showed a tendency to be less dyskinetic than controls throughout the study. 
Nonetheless, a significant attenuation of dyskinesia was observed at first administration 
(day 1; treatment, F1,8=2.55, p=0.13; time, F8,128=8.99, p<0.0001, time × treatment 
interaction F8,128=2.51, p=0.0143) (Fig. 7B). This effect, however, disappeared in 
subsequent experimental sessions (Fig. 7C-E).  
At days 3, 8, 14 and 19, rotarod activity was evaluated at 60 min after L-DOPA 
administration (treatment, F3,3=5.89, p=0.0025; time, F3,96=3.14, p=0.0289, time × 
treatment interaction F9,96=0.62, p=0.77) (Fig 7F). ANOVA revealed that rats treated with 
L-DOPA alone poorly performed on the rotarod from the first through the last session,
whereas animals treated with 0.03 mg kg
-1
 AT-403 were significantly impaired only at day
19.  
Effects on ERK phosphorylation 
D1 receptor activation increases pERK levels in striatal MSNs (Valjent et al., 2005), and 
elevated pERK levels are associated with LID (Pavon et al., 2006; Santini et al., 2007). We 
therefore investigated whether AT-403 could reduce D1 agonist-stimulated pERK levels in 
striatum. In the first set of experiments (Fig. 8A), application of the D1 agonist SKF38393 
(100 µM) to striatal slices of naïve mice caused a ~4-fold increase in the number of pERK 
immunoreactive cells. AT-403 alone tended to reduce basal pERK levels and, when co-
applied with SKF38393, prevented its effect (AT-403 F1,44=29.20 p<0.0001; SKF38393 
F1,44=43.30 p<0.0001; interaction F1,44=29.61 p<0.0001). We therefore investigated 
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whether AT-403 could also be effective in vivo (Fig. 8B-C; Supporting Information Figure 
S1). 6-OHDA dyskinetic rats were pretreated with saline or AT-403 0.1 mg kg
-1
 and 15 
min later, challenged with L-DOPA. Dyskinetic animals showed a 40% increase of pERK 
levels in the ipsilateral compared to the contralateral striatum whereas AT-403-treated 
dyskinetic and 6-OHDA hemilesioned rats showed similar levels in both striata (Fig. 8B; 
F5,42=5.96, p=0.0003). Indeed, pERK levels at the ipsilateral side were normalized in AT-
403-treated dyskinetic rats compared to dyskinetic controls and 6-OHDA hemilesioned 
rats. Interestingly, statistical analysis also revealed a ~30% reduction in pERK levels at the 
contralateral side in AT-403-treated dyskinetic rats compared to 6-OHDA hemilesioned 
rats. AT-403 did not affect total ERK levels (Fig. 8C), showing the effect was specific for 
the phosphorylated form of the protein. 
 
 
Discussion 
AT-403 and AT-390 are novel small-molecule NOP receptor agonists with affinity, 
potency, and selectivity for the NOP receptor better than those of our previously used NOP 
agonist Ro 65-6570 (Marti et al., 2012), and in line with most potent and selective NOP 
receptor agonists described thus far (Zaveri, 2016). In vivo, both AT-403 and AT-390 
significantly improved parkinsonian-like akinesia at low doses and disrupted motor 
coordination and global behaviour at higher ones. AT-403 was remarkably potent, 10-fold 
more than AT-390, causing behavioural effects at doses as low as 0.01 mg kg
-1
, and overt 
sedation at 0.3 mg kg
-1
. Various studies have shown that genetic deletion or 
pharmacological blockade of the NOP receptor improve motor activity in naïve mice, rats 
and nonhuman primates (Candeletti et al., 2000; Marti et al., 2004b; Marti et al., 2008; 
Rizzi et al., 2011; Viaro et al., 2008) suggesting that endogenous N/OFQ tonically inhibits 
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motor behaviour. Motor inhibition is also typically observed when intermediate-to-high 
doses of the natural agonist N/OFQ are exogenously administered. However, exogenous 
N/OFQ is capable of promoting movement when given at low doses (Florin et al., 1996; 
Kuzmin et al., 2004; Marti et al., 2009; Viaro et al., 2013), an effect that originates from 
changes of primary motor cortex activity (Marti et al., 2009). The biphasic effect on motor 
function produced by AT-403 and AT-390 is similar to that of the NOP receptor agonist 
SCH 655842 in mice, where low doses stimulated and higher doses inhibited total distance 
travelled (Lu et al., 2011). Nonetheless, not all small-molecule NOP receptor agonists 
replicate this profile, since Ro 64-6198 caused only inhibition (Kuzmin et al., 2004). The 
finding that low doses of AT-403 and AT-390 reduced the immobility time in the catalepsy 
test, and that this effect persisted also at doses inhibiting rotarod performance, would 
indicate a specific control operated by NOP receptors on neuronal circuits regulating time 
to initiate movement, i.e. akinesia. Indeed, the effect is clearly mediated by NOP receptors, 
since it was reversed by SB-612111, at doses per se ineffective on motor function. The 
reason why AT-403 and AT-390 did not also affect stepping activity or rotarod 
performance at these low doses may be due to plastic changes of N/OFQ transmission in 
the parkinsonian brain. In particular, since N/OFQ tone is reduced in some areas (e.g. 
striatum) and elevated in others (e.g. SNr), we speculate that AT-403 and AT-390 may 
target specific subpopulations of NOP receptors that are not saturated by endogenous 
N/OFQ, or that are even up-regulated, perhaps as a compensatory response following the 
drop of N/OFQ levels (Marti et al., 2012). Alternatively, we must consider the possibility 
that the reduction of immobility time may reflect changes in non-motor functions. Indeed 
in rats, NOP receptor agonists exert anxiolysis at low, non-sedative doses (Jenck et al., 
2000; Lu et al., 2011; Varty et al., 2008). However, the finding that Ro 65-6570 
ameliorated axial symptoms in MPTP-treated nonhuman primates (Marti et al., 2012) 
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seems to confirm the view that NOP receptor stimulation can exert positive motor effects, 
even under parkinsonian conditions, in different animal species.    
We previously reported that the poorly NOP-selective (10-fold over µ receptor) small-
molecule NOP agonist Ro 65-6570, reduced LID expression without causing primary 
hypolocomotion (Marti et al., 2012). The present study confirms that NOP receptor 
stimulation counteracts the emergence of dyskinesia. Nonetheless, only for AT-403 it was 
possible to find a (narrow) therapeutic window where inhibition of LID was not associated 
with sedation/hypolocomotion. In fact, the antidyskinetic effect of 0.03 mg kg
-1
 AT-403 
was associated with improvement of rotarod performance ON L-DOPA, as previously 
shown for Ro 65-6570, and as expected from drugs that reduce dyskinetic movements 
thereby improving motor coordination (Marti et al., 2012). We cannot prove whether the 
antidyskinetic and the sedative effects are temporally-spaced aspects of a common 
behavioural response or, if they are independent phenomena instead. In support of the 
latter however, we showed that N/OFQ injection in the striatum, i.e. a brain area not 
specifically involved in attention control, inhibited AIMs expression (Marti et al., 2012). 
Moreover, we found that AT-403 was capable of inhibiting D1-receptor stimulated 
expression of Extracellular Signal-Regulated Kinase (ERK), a biochemical fingerprint of 
LID, in vitro and ex-vivo, suggesting that the antidyskinetic effect of NOP agonists 
specifically relies on the NOP receptor ability to negatively interfere with D1 signaling in 
direct pathway striatal MSNs neurons (Marti et al., 2012). The finding that pERK levels at 
the contralateral side were reduced in AT-403-treated rats compared to 6-OHDA 
hemilesioned rats is consistent with this view. This raises the possibility that the 
antidyskinetic and sedative/hypolocomotive have different neuroanatomical substrates and 
can be pharmacologically parsed. In fact, not all NOP agonists tested thus far displayed the 
same thresholds for antidyskinetic and sedative responses. For instance, Ro 65-6570 
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exerted motor inhibition at doses (1 mg kg
-1
) higher than those attenuating dyskinesia (0.01 
mg kg
-1
) whereas for AT-390 the two responses were superimposable. The wideness of the 
therapeutic window may thus be compound-dependent and relate to several 
pharmacodynamic/pharmacokinetic reasons, among which selectivity/activity against 
different populations of NOP receptors (or NOP receptor-regulated motor pathways), 
different brain penetrance in brain areas mediating the two effects, or different off-targets. 
Moreover, recent studies pointed out that Ro 65-6570 is a G protein biased ligand, being 
less efficient in activating the β-arrestin2 pathway than N/OFQ (Ferrari et al., 2016) or AT-
403 (Ferrari et al., 2017). A different efficacy towards the Gi and β-arrestin2 pathways 
may thus result in a dissociation between the antidyskinetic and sedative effects. 
The ability of AT-390 to prolong AIMs duration was surprising. This effect was dose-
dependent, and likely unrelated to the mechanisms underlying the delay in AIMs 
appearance since it was not shared by AT-403. Interestingly, it was shown that Ro 65-6570 
potentiated cocaine-induced locomotion. Both L-DOPA and cocaine are capable of 
elevating striatal dopamine (DA) levels, and indirect evidence that NOP agonists improve 
DA transmission has been presented. In fact, the motor stimulating effect of N/OFQ is 
blocked by a D2 antagonist or by genetic removal of the D2 receptor (Florin et al., 1996; 
Viaro et al., 2013). Therefore, the prolongation of L-DOPA effect might rely on a 
prolonged DA output. Interestingly, we previously showed that NOP antagonists can also 
promote movement by elevating D2 transmission (Viaro et al., 2013), and are capable of 
potentiating L-DOPA therapeutic effects, at the cost of inducing dyskinesia (Marti et al., 
2012; Visanji et al., 2008). Therefore, low degree stimulation of NOP receptors and NOP 
receptor blockade appear to share similar mechanisms and motor effects (Viaro et al., 
2013). However, prolongation of AIMs duration was not previously reported with Ro 65-
6570 or N/OFQ itself (Marti et al., 2012). Therefore, alternative explanations should be 
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taken into account, such that AT-390 stimulates specific subpopulation of NOP receptors, 
inhibits enzymatic degradation of synaptic DA (newly formed from L-DOPA) or even L-
DOPA itself, or has off-target effects. Nonetheless, the ability of AT-390 to prolong L-
DOPA action deserves further investigation. In fact, the prolongation of L-DOPA action 
might help minimize long-term side effects of the drug, such as dyskinesia and motor 
fluctuations, which are due to oscillations of L-DOPA plasma levels and, consequently, 
DA brain levels. 
Chronic administration of 0.03 mg kg
-1
 AT-403 failed to affect overall LID development, 
suggesting that NOP receptor stimulation with such low dose of AT-403 does not prevent 
the sensitization (i.e. priming) of striatal MSNs to L-DOPA. Nonetheless, AT-403 
significantly reduced AIMs appearance at first administration and, consistently, spared 
rotarod performance ON L-DOPA. Thus, we might speculate that the inability of AT-403 
to prevent the priming to L-DOPA is due to development of NOP receptor desensitization. 
Indeed, receptor tolerance to the analgesic effect can develop after prolonged exposure to 
NOP agonists (Khroyan et al., 2007; Micheli et al., 2015). If this were the case, a NOP 
receptor partial agonist might exert a prolonged efficacy, due to its lower propensity to 
desensitize the receptor. In addition, such a molecule might provide additional 
symptomatic benefit due to its ability to attenuate overactive N/OFQ transmission in SNr, 
which appears to contribute to motor deficit in parkinsonism models (Marti et al., 2005; 
Marti et al., 2012). However, we should note that other behavioural responses to NOP 
receptor agonists, such as the anxiolytic effect of Ro 64-6198 (Dautzenberg et al., 2001) or 
the protective effect on alcohol drinking of MT-7716 (Ciccocioppo et al., 2014) do not 
undergo tolerance after repeated administration. Alternatively, we can speculate that the 
modulation operated by such a low dose of AT-403 is insufficient to fully counteract LID 
development, being effective only when the process is in its initial phase. In this respect, 
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since the antidyskinetic effect of AT-403 might rely on a negative NOP-D1 receptor 
functional interaction in direct pathway striatal MSNs, higher AT-403 doses (e.g. 0.1 mg 
kg
-1
) would prove more effective. However, these doses are burdened by severe sedation, 
and whether repeated administration widens the therapeutic window, having a different 
impact on the thresholds of the antidyskinetic and the sedative effects, cannot be predicted. 
Conclusions 
The novel small molecule NOP receptor agonists, AT-390 and AT-403, were used to 
investigate the effect of NOP receptor stimulation on parkinsonian-like disabilities and 
LID in 6-OHDA hemilesioned rats. Both compounds selectively improved akinesia at low 
doses, and disrupted motor coordination and general behaviour at higher ones, confirming 
that NOP receptor stimulation biphasically regulates motor function. AT-403 also provided 
a specific, albeit mild, therapeutic effect in protocols of LID expression and development, 
which was associated with inhibition of biochemical marker of D1 receptor-induced 
striatal MSNs activation. These data confirm that, beyond their well characterized anti-
reward, anxiolytic and analgesic effects (Zaveri, 2016), NOP receptor agonists may be 
therapeutically useful to attenuate dyskinesia in L-DOPA-treated parkinsonian patients 
(Marti et al., 2012). Nonetheless, further studies are needed to pin down the 
neurobiological substrates of the antidyskinetic and sedative/hypolocomotive effects in 
order to develop NOP receptor agonists with an optimal therapeutic window.  
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Figure legends 
Figure 1. Timelines of studies in 6-OHDA rats. Timelines of studies on motor disabilities  
(upper panel), dyskinesia expression (middle panel) and dyskinesia development (lower 
panel). RBD, bar, drag e rotarod sessions. A, AIMs scoring. R, rotarod sessions. 
 
Figure 2. Effect of AT-403 on parkinsonian disabilities. Motor activity of 6-OHDA 
hemilesioned rats was evaluated in the bar (A), drag (B) and rotarod (C) tests, before, 30 
min and 90 min after vehicle or AT-403 administration (0.001, 0.001, 0.03 and 0.1 mg kg
-
1
, s.c.). Data are expressed as immobility time (in sec, A), number of steps (B) and time on 
rod (in sec, C), and are means ± SEM of n=14 determinations per group. Statistical 
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analysis was performed by two-way RM ANOVA followed by the Bonferroni test for 
multiple comparisons *p<0.05, different from vehicle.  
  
Figure 3. NOP receptor specificity of the AT-403 effect. The NOP receptor antagonist 
SB-612111 (0.01 mg kg
-1
, s.c.) was challenged against a low dose of AT-403 (0.01 mg kg
-
1
, s.c.), and the effect evaluated in the bar test. Data are expressed as immobility time (in 
sec) and are means ± SEM of n=9 (vehicle, AT-403, SB-612111) or n=8 (AT-403+SB-
612111; one data discarded due to experimental loss) determinations per group. Statistical 
analysis was performed by one-way ANOVA followed by the Newman-Keuls test for 
multiple comparisons. *p<0.05, different from vehicle, #p<0.05, different from AT-403.  
  
Figure 4. Effect of AT-390 on parkinsonian disabilities. Motor activity of 6-OHDA 
hemilesioned rats was evaluated in the bar (A), drag (B) and rotarod (C) tests, before, 60 
min, 120 min and 180 min after vehicle or AT-390 administration (0.1, 0.3 and 1 mg kg
-1
, 
s.c.). Data are expressed as immobility time (in sec, A), number of steps (B) and time on 
rod (in sec, C), and are means ± SEM of n=9 (vehicle, AT-390 0.3 mg kg
-1
, AT-390 1 mg 
kg
-1
) determinations per group. The effect of AT-390 0.01 mg kg
-1
 was also assessed, 
although in a lower number of rats (n=5). Statistical analysis was performed by two-way 
RM ANOVA followed by the Bonferroni test for multiple comparisons *p<0.05, *p<0.05, 
significantly different from vehicle.  
 
Figure 5. AT-403 attenuated the expression of L-DOPA-induced dyskinesia. Axial, limb 
and orolingual (collectively ALO) abnormal involuntary movements (AIMs) were scored 
in 6-OHDA hemilesioned dyskinetic rats following challenge with L-DOPA (6 mg kg
-1
 
plus benserazide 12 mg kg
-1
, s.c., n=16) combined with vehicle (s.c., n=16), AT-403 0.03 
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mg kg
-1
 (s.c., n=15; one data point was discarded as the animal did not respond to L-
DOPA) or AT-403 0.1 mg kg
-1
 (s.c., n=16). Data (means ± SEM) are expressed as ALO 
AIMs score for each-time point in absolute values (A) or as separate axial, limb and 
orolingual AIMs scores over the 3 hr observation period (i.e. cumulative scores calculated 
as the sum of scores at each time-point; B). On a separate day, treatments were replicated 
in the same animals, and rotarod performance (time on rod in sec, n=10 determinations per 
group) was evaluated before and 60 min after drug administration (C). *p<0.05, 
significantly different from vehicle. #p<0.05 different from vehicle ON L-DOPA. 
Statistical analysis was performed by two-way RM (A) or two-way (C) ANOVA followed 
by the Bonferroni test for multiple comparisons or one-way ANOVA followed by the 
Newman-Keuls test for multiple comparisons (B).   
 
 
 
Figure 6. AT-390 delayed and prolonged the expression of L-DOPA-induced dyskinesia. 
Axial, limb and orolingual (collectively ALO) abnormal involuntary movements (AIMs) 
were scored in 6-OHDA hemilesioned dyskinetic rats following challenge with L-DOPA 
(6 mg kg
-1
 plus benserazide 12 mg kg
-1
, s.c.) combined with vehicle or AT-390 (0.3 or 1 
mg kg
-1
, s.c., n=8 determinations per group). The effect of AT-390 3 mg kg
-1
 was 
evaluated separately in a small number of rats (n=4). Data (means ± SEM) are expressed as 
ALO AIMs score for each-time point in absolute values (A,C) or as separate axial, limb 
and orolingual AIMs scores over the 3 hr observation period (i.e. cumulative scores 
calculated as the sum of scores at each time-point; B). On a separate day, treatments were 
replicated in the same animals, and rotarod performance was evaluated (as time on rod in 
sec; n=6 determinations per group) before and 60 min after drug administration (D). 
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*p<0.05, significantly different from L-DOPA+vehicle. Statistical analysis was performed 
by two-way RM (A) or two-way (D) ANOVA followed by the Bonferroni test for multiple 
comparisons or one-way ANOVA followed by the Newman-Keuls test for multiple 
comparisons (B).   
  
Figure 7. Chronic treatment with AT-403 significantly inhibited L-DOPA-induced 
dyskinesia at day 1, however without interfering with its overall development. Axial, limb 
and orolingual (collectively ALO) abnormal involuntary movements (AIMs) were scored 
in 6-OHDA hemilesioned rats chronically-treated for 20 days with L-DOPA (6 mg kg
-1
 
plus benserazide 12 mg kg
-1
, s.c.) combined with vehicle or AT-403 0.03 mg/Kg (s.c., n=9 
rats per group). The time-course of AIMs development over the 20-day period (A), and the 
AIMs response separately at days 1 (B), 9 (C), 20 (D) and 21 (challenge, E) are shown. In 
days different from AIMs scoring, rotarod performance was evaluated (as time on rod in 
sec) before and 60 min after drug administration (F). *p<0.05, significantly different from 
vehicle. Statistical analysis was performed by two-way RM ANOVA followed by 
Bonferroni test for multiple comparisons.   
 
Figure 8. AT-403 inhibited D1 receptor-stimulated ERK signalling in striatum. Number 
of ERK-positive cells in striatal slices of naïve mice following simultaneous application of 
SKF38393 and AT-403 (30 nM) (A) and representative microphotographs of treated slices. 
Data are mean±SEM of n=12 slices per group, obtained from 6 mice and pooled together. 
*p<0.05, significantly different from not stimulated vehicle, #p<0.05 significantly different 
from SKF38393 alone (two-way ANOVA followed by the Bonferroni post-hoc test). 
Western blot representative images (upper panel) and quantification (lower panel) of 
pERK  (B) and total ERK (C) in the striatum of 6-OHDA hemilesioned, L-DOPA-naïve or 
Page 34 of 45
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
35 
L-DOPA primed, dyskinetic rats. Dyskinetic rats were treated with 0.1 mg kg
-1
 AT-403 or
vehicle, and 15 min later challenged with L-DOPA. Data are means ± SEM of n=8 rats per 
group. *p<0.05, significantly different from the ipsilateral side of L-DOPA treated rats, 
#p<0.05 significantly different from the contralateral side of control rats (one-way 
ANOVA followed by the Newman-Keuls post-hoc test). 
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Table 1. Receptor binding assays (upper panel) and [
35
S]GTPγS functional activity (lower 
panel) of NOP agonists in membranes of CHO cells stably expressing the human 
recombinant NOP and classical µ, δ and κ receptors. Experiments were performed as 
previously described (references in text). Values represent average ± SEM for three 
experiments conducted in triplicate. Standard ligands in binding and [
35
S]GTPγS 
experiments were N/OFQ (NOP), DAMGO (µ), DPDPE (δ) and U69,593 (κ). Affinity 
values (Ki, nM) were 0.12±0.01 for N/OFQ, 2.96±0.54 for DAMGO, 1.11±0.07 for 
DPDPE and 1.05±0.02 for U69,593. Efficacy (EC50 nM) of standard ligands in the 
[
35
S]GTPγS was 3.6±0.7 for N/OFQ, 32.6±4.06 for DAMGO, 8.98±2.31 for DPDPE and 
60.14±7.45 for U69,593. Agonist stimulation by AT-390 and AT-403 are expressed as a 
percentage of that of the standard agonist taken as 100. 
 Binding (Ki  nM) 
NOP Μ δ κ 
AT-390 0.9 ± 0.32 53.13 ± 16.5 113.15 ± 9.8 85.28 ± 19.8 
AT-403 1.13 ± 0.13 97.94 ± 15.0 4074.3 ± 17.3 1563.74 ± 203.9 
 
[35S]GTPγS assay 
 NOP Μ δ κ 
EC50 % Stim EC50 % Stim EC50 % Stim EC50 % Stim 
AT-390 15.20 ± 0.4 110.1 ± 11.4 143.80 ± 0.6 54.3 ± 9.4 3847.0 ± 73 61.3 ± 6 534.3 ± 147.2 19.25 ± 1.3 
AT-403 6.3 ± 1.42 104.6 ± 1.2 206.4 ± 78.9 33.5 ± 14.6 ------ ------ ------ ------ 
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